Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2017

View Archived Issues

FDA grants orphan drug designation to PLX-200 for late infantile neuronal ceroid lipofuscinosis

Humanigen, new name for KaloBios

Selvita partners with the Leukemia & Lymphoma Society to advance SEL-120

VDAC-1 targeted to inhibit apoptosis in Alzheimer's disease

Cellectar Biosciences reports positive results from phase I study of CLR-131 in multiple myeloma

La Jolla Pharmaceutical launches expanded access program for LJPC-501

MilliporeSigma and Baylor College of Medicine to develop vaccines for neglected diseases

First animal model of sporadic Alzheimer's disease created and characterized

Nuclear receptor ROR-gamma antagonism proposed for treating Crohn's disease

Kite Pharma submits IND for KITE-585

Galena Biopharma, SELLAS Life Sciences Group enter merger agreement

Encouraging data presented from first cohort in phase Ib study of TD-1473 in ulcerative colitis

GlaxoSmithKline patents HIV maturation inhibitors

Biogen describes novel IRAK-4 inhibitors

Humanigen completes benznidazole bioavailability study

Shanghai Hengrui, Jiangsu Hengrui Medicine describe new anti-PCSK9 antibodies

PreveCeutical Medical and UniQuest sign a nonbinding letter of intent

Stanford and Washington University present immunoconjugates including chemerin

Positive topline data from phase II trial of bempedoic acid/ezetimibe combination plus atorvastatin

University of Southern Denmark discloses bispecific antibodies targeting CD73

DNA aptamers binding integrin alpha-6 patented by Universitaet Hamburg and UKE

Brigham and Women's Hospital describes CRISPR/Cas miR-10a/b editing complexes

House dust mite-derived allergen immunomodulators synthesized at Dankook University

Fujifilm initiates a phase I study of FF-10101 in relapsed or refractory acute myeloid leukemia

Stivarga approved in Europe for the second-line systemic treatment of liver cancer

Mitobridge begins clinical development of MA-0211

Dermira to license exclusive worldwide rights to lebrikizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...